欢迎来到天天文库
浏览记录
ID:58298309
大小:1.29 MB
页数:6页
时间:2020-05-03
《卵巢癌腹水CD4+CD25+调节性T细胞免疫抑制功能及机制的研究-论文.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、560中国肿瘤临床2014年第41卷第9期ChinJClinOncol2014,Vo1.41,No.9www.cjco.en卵巢癌腹水CD4+CD25+调节性T细胞免疫抑制功能及机制的研究术姚海荣田菁李迎春张文琪郝权摘要目的:研究卵巢癌患者腹水内CD4+CD25+调节性T.~/k]g(Treg)免疫抑制功能与患者临床病理特点的关系及其与患者初治及复发状态是否相关,并进一步探讨卵巢癌腹水内CD4+CD25+调节性T细胞(Treg)发挥免疫调节性作用的具体机制。方法:应用免疫磁珠分选法分选28例卵巢癌患者腹
2、水内CD4+CD25+调节性T细胞及CD4+CD25一T细胞,采用羧基荧光素二醋酸盐琥珀酰亚胺酯(carb0xv玎uoresceinsuccinimidvlester,CFSE)标记CD4+CD25一T细胞,CD4+CD25+Treg与自体CFSE标记CD4+CD25一T细胞以1:1比例共培养,经流式检测CFSE表达及Modfit软件分析CD4+CD25一T增殖指数(PI),计算各标本内Treg对自体CD4+CD25一T细胞增殖抑制率。应用中合性抗IL一10抗体及中合性抗TGF—B1抗体探究腹水内CD4
3、+CD25+Treg介导免疫逃逸作用是否通过抑制性细胞因子IL一10或TGF—B1发挥作用。结果:Ⅲ~Ⅳ期卵巢癌腹水内CD4+CD25+Treg对自体CD4+CD25一T细胞增殖抑制率为(75.72+17.04)%,较I~Ⅱ期Treg抑制率(59.61+16.97)%显著增强(P4、抗IL一10抗体或/及中和性抗TGF一131抗体,Treg对自体CD4+CD25一T细胞增殖抑制率较对照组均显著降低(P<0.05)。结论:卵巢癌腹水内CD4+CD25+Treg介导免疫逃逸能力与肿瘤分期及复发、初治状态相关,且发挥免疫逃逸作用可能是与分泌抑制性细胞因子IL一107LTGF—B1有关。关键词卵巢癌调节性T细胞腹水复发doi:10.3969/j.issn.1000—8179.20l32020Immuno.suppressionandmechanismOfCD4+CD25+Tcellsina5、scitesofovariancancerpatientsHairongYAO,JingTIAN,YingchunLI,WenqiZhANG,QuanHAOCorrespondenceto:QuanHAO;E·mail:haoquandoctor@126.cornDepartmentofGynecologicOncology,TianjinMedicalUniversityCancerInstituteandHospital,TianjinKeyLaboratoryofCan—cerPrevention6、andTreatment,Tianjin300060,China.ThisworkwassupportedbytheFundsofTianjinMunicipalResearchProgramforBasicSciencesandFrontierTechnology(NO.12JCYBJC17000).AbstractObjective:Thisresearchexplorestherelationshipbetweentheimmuno—suppressionfunctionofregulatoryT7、cells(Treg)intheascitesofovariancancer(OC)patients,theclinico—pathologicfeaturesofthesepatients,andthecorrelationofthefunctionofTregwithinitialtreatmentandrelapsestatusofthepatientstofurtherinvestigatethespecificmechanismofimmuno-regulatoryfunc-tionofCD48、+CD25+TregintheascitesofOC.Methods:Immuno—magneticactivatedcellsorting(MACS)wasconductedtosortCD4+CD25+TregandautologousCD4+CD25一Tregfromtheascitesof28OCpatients.Carboxyfluorescein—diacetatesuccinimidylester(CFSE)wasusedto
4、抗IL一10抗体或/及中和性抗TGF一131抗体,Treg对自体CD4+CD25一T细胞增殖抑制率较对照组均显著降低(P<0.05)。结论:卵巢癌腹水内CD4+CD25+Treg介导免疫逃逸能力与肿瘤分期及复发、初治状态相关,且发挥免疫逃逸作用可能是与分泌抑制性细胞因子IL一107LTGF—B1有关。关键词卵巢癌调节性T细胞腹水复发doi:10.3969/j.issn.1000—8179.20l32020Immuno.suppressionandmechanismOfCD4+CD25+Tcellsina
5、scitesofovariancancerpatientsHairongYAO,JingTIAN,YingchunLI,WenqiZhANG,QuanHAOCorrespondenceto:QuanHAO;E·mail:haoquandoctor@126.cornDepartmentofGynecologicOncology,TianjinMedicalUniversityCancerInstituteandHospital,TianjinKeyLaboratoryofCan—cerPrevention
6、andTreatment,Tianjin300060,China.ThisworkwassupportedbytheFundsofTianjinMunicipalResearchProgramforBasicSciencesandFrontierTechnology(NO.12JCYBJC17000).AbstractObjective:Thisresearchexplorestherelationshipbetweentheimmuno—suppressionfunctionofregulatoryT
7、cells(Treg)intheascitesofovariancancer(OC)patients,theclinico—pathologicfeaturesofthesepatients,andthecorrelationofthefunctionofTregwithinitialtreatmentandrelapsestatusofthepatientstofurtherinvestigatethespecificmechanismofimmuno-regulatoryfunc-tionofCD4
8、+CD25+TregintheascitesofOC.Methods:Immuno—magneticactivatedcellsorting(MACS)wasconductedtosortCD4+CD25+TregandautologousCD4+CD25一Tregfromtheascitesof28OCpatients.Carboxyfluorescein—diacetatesuccinimidylester(CFSE)wasusedto
此文档下载收益归作者所有